Recent Updates
Recently added Catalysts
COCP

PRESENTATION Untitled Document

Monday, January 9, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PRESENTATION Untitled Document

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
10.7%
average across 4 past catalysts
Cash runway
~2 mo
High dilution risk
Lead asset
CDI-31244
Phase 2 · Chronic Hepatitis C

Full Press Release Details

PRESENTATION Untitled Document.
ShareAdd on Google
Tags: COCP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 9, 2017

Biotech snapshot

Cash runway
$2M liquidity · $1M/mo burn
~2 mo
High dilution risk
Lead asset
CDI-31244Phase 2
Chronic Hepatitis C →

Catalyst track record

+67%
best trade around COCP's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for COCP.

See every catalyst's timing & PoA →